United Therapeutics Corporation  

(Public, NASDAQ:UTHR)   Watch this stock  
Find more results for UTHR
130.62
-0.65 (-0.50%)
Real-time:   2:24PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 129.81 - 131.30
52 week 110.90 - 169.89
Open 130.52
Vol / Avg. 155,210.00/632,759.00
Mkt cap 5.67B
P/E 15.22
Div/yield     -
EPS 8.58
Shares 43.44M
Beta 1.51
Inst. own 108%
Oct 25, 2017
Q3 2017 United Therapeutics Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 15, 2017
United Therapeutics Corp at Wedbush PacGrow Healthcare Conference - Webcast
Jul 27, 2017
Q2 2017 United Therapeutics Corp Earnings Release
Jul 27, 2017
Q2 2017 United Therapeutics Corp Earnings Call - Webcast
Jun 28, 2017
United Therapeutics Corp Annual Shareholders Meeting
Jun 21, 2017
United Therapeutics Corp Annual Shareholders Meeting (Estimated)
Jun 6, 2017
United Therapeutics Corp at Jefferies Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -12.60% 44.64%
Operating margin 9.45% 66.41%
EBITD margin - 68.38%
Return on average assets -8.55% 31.65%
Return on average equity -11.60% 41.23%
Employees 750 -
CDP Score - -

Address

1040 SPRING ST
SILVER SPRING, MD 20910
United States - Map
+1-301-6089292 (Phone)
+1-301-6089291 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Officers and directors

Martine A. Rothblatt Ph.D. J.D. Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Michael Benkowitz President, Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Christopher Patusky J.D. Lead Independent Vice Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
James C. Edgemond Chief Financial Officer, Treasurer
Age: 49
Bio & Compensation  - Reuters
Paul A. Mahon J.D. Executive Vice President, General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Raymond A. Dwek Non-Independent Director
Age: 75
Bio & Compensation  - Reuters
Christopher Causey Independent Director
Age: 54
Bio & Compensation  - Reuters
Richard A. Giltner Independent Director
Age: 53
Bio & Compensation  - Reuters
Katherine J. Klein Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Raymond C. Kurzweil J.D. Independent Director
Age: 69
Bio & Compensation  - Reuters